30 closest matches · ranked by relevance
Multiple Myeloma
Primary: International Myeloma Working Group (IMWG) Response Criteria — 8; 4; 7; 19 participants
Recurrent Mantle Cell Lymphoma
Primary: Number of Participants With an Overall Response Defined as Complete Response and Partial Response — 21 participants
Multiple Myeloma
Primary: The Proportion of Patients Alive and Without Progressive Disease (PD) for ≥6 Months — 75 percentage of treated patients
Relapsed and Bortezomib Refractory Multiple Myeloma · Refractory Multiple Myeloma · Multiple Myeloma in Relapse
Primary: Overall Response Rate (PR+nCR+CR) — 34.5 percentage of participants
Multiple Myeloma
Primary: Overall Response Rate (PR or Better) of Vorinostat in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory MM Refractory to a Previous…
Refractory Multiple Myeloma
Primary: Find Maximum Tolerated Dose (MTD) of Bortezomib in Combination With Pomalidomide and Dexamethasone Out to 2.5 Years, by Count of Patients With Dose Limiting Toxicities…
Relapsed or Refractory Multiple Myeloma
Primary: Overall Response Rate (ORR) As Assessed by the Independent Review Committee (IRC) — 57.7 percentage of participants
Multiple Myeloma
Primary: Median Progression-Free Survival (PFS) — 8.5 Months
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: Proportion of Confirmed Responses With Ixazomib Citrate Alone (Arm A [Closed]), Ixazomib Citrate With Dexamethasone (Arms B + C), or With Dexamethasone and…
Multiple Myeloma
Primary: Overall Response Rate (ORR) — 62.2; 65.1; 50.6 percentage of participants
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: Progression-free Survival at 18 Months (PFS18) Defined as the Proportion of Patients Alive and Free From Disease Progression at 18 Months From Study Entry — 0.3750…
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: Proportion of Confirmed Tumor Responses Defined to be a Partial Response or Better Noted as the Objective Status on Two Consecutive Evaluations — .4; .25 proportion of…
Multiple Myeloma
Primary: Objective Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 15 percentage of participants
Multiple Myeloma
Primary: Time to Progression of Disease — 12.6; 9.9 Months — p=0.196
Multiple Myeloma
Primary: Participants With Dose Limiting Toxicity (DLT) — 0; 0; 0 participants
Multiple Myeloma and Plasma Cell Neoplasm
Primary: 6B Antibody Response to Prevnar Vaccine in Peripheral Blood — 3.69; 7.58 fold change
Multiple Myeloma
Primary: Best Overall Response Rate (ORR) — 16.7; 23.7 % of participants w/ PR or better
Multiple Myeloma in Relapse · Stage II Multiple Myeloma · Stage III Multiple Myeloma
Primary: Confirmed Anti-tumor Response Rate (Complete Response and Partial Response) to the Combination of Bevacizumab and Lenalidomide — 64 percentage of participants
Refractory Multiple Myeloma
Primary: Dose-limiting Toxicity (DLT) (Phase I) — 0; 0; 0; 0 participants
Multiple Myeloma
Primary: Progression Free Survival by Independent Response Adjudication Committee (IRAC) — 11.20; 7.10 Months — p=0.001
B-cell Adult Acute Lymphoblastic Leukemia (ALL) · Ph-positive Adult Acute Lymphoblastic Leukemia (ALL) · Recurrent Adult Acute Lymphoblastic Leukemia (ALL)
Primary: Response Rate (RR) — 11 Participants
Relapsed/Refractory Multiple Myeloma
Primary: Progression Free Survival (PFS) as Per Intention-to-treat (ITT) — 2.6; 1.7 months — p==0.0054
Multiple Myeloma
Primary: Progression-free Survival Events in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination…
Multiple Myeloma
Primary: Plerixafor Maximum Tolerated Dose (MTD) [Phase I] — 320 ug/kg
Multiple Myeloma
Primary: Maximum Tolerated Dose (MTD) of Carfilzomib and Pegylated Liposomal Doxorubicin (Phase I - Part 1). — 56; 30 mg/m^2
Multiple Myeloma
Primary: Objective Response Rate (ORR), Defined as the Combined Rate of Complete Response, Partial Response and Minimal Response — 0; 0; 3; 11 percentage patients
Multiple Myeloma
Primary: Bone Mineral Density (BMD) — 0.14; -2.68 T-scores
Multiple Myeloma
Primary: To Establish the Safety, Tolerability, and RP2D (Phase 1); To Assess the Overall Response Rate in Subjects With Advanced Multiple Myeloma (Phase 2). — 95; 3; 3; 3…
Multiple Myeloma
Primary: Overall Best Confirmed Response — 101; 6 number of participants
Refractory Plasma Cell Myeloma
Primary: Number of Patients Surviving Progression-free — 14 Participants